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Meije et al. 2 demonstrated that DNAemia was detected persistently for several weeks before the development of six cases of invasive aspergillosis (IA): one proven and five probable cases. Indeed DNAemia was found to be a very early marker of IA, being detected on an average of 21 days before signs were apparent on high-resolution computed tomography and 68 days before galactomannan was first detected. By contrast, Blennow et al. 4 monitored a series of allogeneic hematopoietic SCT recipients who had undergone reduced-intensity conditioning for fungal PCR and found no association between IA and DNAaemia.
Both studies differed fundamentally in the sampling frequency, the patient populations and the nature of antifungal prophylaxis; such differences in the study design may be one explanation for the diverse results.
Furthermore, differences in methodology may have a crucial role; both studies used different protocols for PCR amplification, different target genes and indicated different limits of detection. Finally, several relevant methodological details were not provided in either publication, though this can be remedied as there have recently been published guidelines on the minimum information necessary for evaluating diagnostic quantitative PCR tests. 5 The origin and nature of Aspergillus DNA in different types of specimens is also an issue, because it is likely that cell-free DNA is directly released from the fungus into serum and plasma, whereas in whole blood, complete fungal elements, perhaps those engulfed by phagocytes, might be present. These specimens obviously require different strategies to release and purify Aspergillus DNA. With whole blood, an additional lysis step is necessary to break up the rigid cell wall of moulds; the EAPCRI took this into account by spiking the blood specimens with whole living A. fumigatus conidia that can be quantified, even though it is unlikely that spores are present in blood during IA.
Furthermore, unlike in most viral and bacterial infections, the fungal load in blood is thought to be very low, which will directly influence PCR results, especially if PCR performance is less than optimal. The necessity of detecting at least one copy of DNA is itself a limitation of PCR, because the risk of contamination increases proportionally, leading to false-positive results as Aspergillus spores are ubiquitous and can be present in high concentrations in the environment. Reagents, including blood collection tubes, can also be contaminated with fungal elements.
Taken together, a direct comparison between different Aspergillus PCR studies is difficult, if not impossible. To counter this, the EAPCRI aims to develop protocols for the standardized use of Aspergillus PCR assays rather than to establish a standard assay. 3, 6 To this end, the EAPCRI has distributed several panels of spiked whole blood and extracted DNA to help identify the variables that have the most impact on the PCR outcome. This has led to defining a standardized approach for Aspergillus PCR testing of whole blood. Extension to other types of specimens such as serum, the inclusion of additional centres, collaboration with the Quality Control for Molecular Diagnostics, organization to establish a proficiency programme and the development of multicentre clinical studies to evaluate the clinical validity and utility of Aspergillus PCR are now in progress.
